Tango Therapeutics股票讨论区

Analysts opine that ongoing losses overshadow higher revenue estimates for Tango Therapeutics. The narrow estimate spread indicates easy valuation or heavy reliance on key assumptions. The company's revenues are predicted to lag behind the industry.

Tango Therapeutics' strong share price surge has led to a soaring P/S, but forecasted future revenues may not support this high P/S ratio. With below-industry-average revenue growth predicted, caution is advised as this could potentially harm long-term share prices.

While slowing growth is anticipated for Tango Therapeutics compared to the wider market, its analysts are optimistic about substantial improvements in the sales pipeline.